Latest News and Press Releases

-数据将展示ADG126的作用机制及与帕博利珠单抗联用连续给药的剂量优化，10 mg/kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究 中国苏州和美国圣地亚哥, Oct. 12, 2023 (GLOBE NEWSWIRE) --...

– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies – SAN DIEGO and SUZHOU, China, Sept. 07, 2023 ...

- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – -...

SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...

SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...

- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors - ...

- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with...

- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology - ...

- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene’s novel...

- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses...